The purpose of this article is to review the incidence and characteristic of first recurrence in a group of 182 patients who underwent curative surgery with extended lymphadenectomy (> or = D2). The median follow up was 46.4 months (range 14-111). The incidence of relapses was 3.3% in the early gastric cancer and 50.8% in the advanced cancer. First recurrence site was systemic in 69.4% of cases and locoregional in 22.6%. The major site of systemic recurrences were peritoneal surface (64.8%), liver (29.5%), and other extra abdominal metastases (5.7%). In 8% of the cases it was not possible to find the site of recurrence. Surgical resection was possible in only 2 out of 14 cases of local recurrence. The incidence of recurrence were directly correlated with the depth of tumor invasion (T1: 3.3%; T2: 20.6%; T3: 61.5%; T4: 70%) and node metastases (NO: 8.3%; N1+: 44.4%; N2+: 64.3%). In advanced cases the incidence of relapses after D1 lymphadenectomy was significantly higher than after D2 lymphadenectomy: 28.6% vs 5.5% in NO cases and 65.6% vs 49.3% in N+ cases. In conclusion it seems that extended lymphadenectomy is associated with a lower incidence of recurrences after curative surgery.

Download full-text PDF

Source

Publication Analysis

Top Keywords

curative surgery
8
extended lymphadenectomy
8
incidence relapses
8
site systemic
8
cases
6
incidence
5
recurrence
5
[recurrence stomach
4
stomach cancer
4
cancer surgery]
4

Similar Publications

Purpose: Synchronous esophageal (EC) and rectal carcinoma (RC) is a rare and challenging condition, particularly in curative-intended treatment. Especially locally advanced tumors may not be suitable for primary resection and require individual multimodal treatment. This review examines curative-intended management of synchronous EC and RC.

View Article and Find Full Text PDF

Quality of Gastrointestinal Surgical Oncology Care According to Insurance Status.

J Gastrointest Surg

January 2025

Division of Surgical Oncology, Department of Surgery, Yale University School of Medicine, New Haven, CT. Electronic address:

Background: Despite efforts to expand insurance coverage, substantial inequalities persist, particularly in cancer treatment. We aimed to evaluate whether quality disparities exist across major insurance plans for patients undergoing curative-intent resection for gastrointestinal (GI) cancers.

Methods: This is a retrospective study of adult patients in the National Cancer Database (NCDB) diagnosed with GI malignant neoplasms between January 1, 2004 and December 31, 2020.

View Article and Find Full Text PDF

Purpose: Anti-programmed cell death 1 (PD1) is the first-choice treatment in patients with advanced cutaneous squamous cell carcinoma (cSCC), when curative options are unavailable. However, reliable biomarkers for patient selection are still lacking.

Experimental Design: In this translational study, clinical annotations, tissue and liquid biopsies were acquired to investigate the association between sustained objective responses and transcriptional profiles, immune cell dynamics in tumor tissue and peripheral blood samples, as well as circulating cytokine levels.

View Article and Find Full Text PDF

Mixed neuroendocrine-non-neuroendocrine neoplasm (MiNEN) of the colon is rare with a poor prognosis. Since the first description of a mixed neoplasm 100 years ago, the nomenclature has evolved, most recently with the 2022 World Health Organization (WHO) classification system. We describe our experience of a case of locoregionally advanced MiNEN of the descending colon treated with curative laparoscopic resection and adjuvant chemotherapy.

View Article and Find Full Text PDF

In order to make the drugs can cure the tumor precisely, this paper establishes the tumor immune dynamic model through the differential equation of tumor growth and analyzes the persistence of the tumor immune model. Research on dual anticancer drugs and commonly used coupling methods is carried out to complete the synthesis of polyethylene glycol dual anticancer drug couplers and the antitumor activity is analyzed to derive the degree of inhibition of polyethylene glycol dual anticancer drugs on tumor activity. From the four judging criteria, it was concluded that the polyethylene glycol bis-anti-cancer drug has a better curative effect on tumor cells.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!